Bharat Biotech has updated the efficacy of Covaxin to 65.2 per cent against the Delta variant in Effectiveness Study on Delta Variant Lancet Infectious Diseases, published on Nov 23 2021.

“Bharat Biotech commends the investigators from the All India Institute of Medical Sciences (AIIMS) on the BBV152 study published in Lancet Infectious Diseases. These results provide evidence for effectiveness for Covaxin in real-life settings,” Bharat Biotech said.

It added that a practical result of 50 per cent achieved during the peak Covid-19 Delta variant wave in India, in a high-risk study population of physicians and health care workers, in a hospital environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin.

“These results compare well with the 65.2 per cent efficacy against the delta variant obtained during the controlled phase III clinical trials of Covaxin conducted among the general population. This study also shows that Covaxin meets the WHO efficacy criteria for Covid-19 vaccines for the dreaded Delta variant,” the company said.